Max Healthcare Institute · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
CGHS wants 30% discount on patented chemotherapy drugs versus MRP, while Max's margins on these drugs are less than 20%, making supply uneconomical. Discussions ongoing for cost-plus arrangement. Management views this as temporary adjustment affecting ~80 crore annual revenue.
Analyst specifically asked about expected losses from Gurgaon greenfield hospital. Management declined to provide guidance, stating it depends on clinician recruitment timing. Historical greenfield losses at Dehradun totaled ~30 crore to break-even in 6 months.
Management acknowledged lessons learned from four insurer disputes but did not confirm whether similar disputes could occur with other insurance companies. The mechanism for annual automatic renewal was only established with those four companies.
Management noted Q3 was severely impacted by lack of vector-borne diseases due to extended monsoon into winter. While Q4 typically benefits from flu season, this remains a recurring demand volatility factor beyond management control.
